{
    "type": "ETP",
    "ucits": false,
    "replication_method": "synthetic",
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": true,
    "complex_factors": [
        "Leverage",
        "Inverse Exposure",
        "Synthetic Replication via Swaps",
        "Daily Reset and Compounding Effects",
        "Counterparty Risk",
        "Complex Futures Rolling",
        "Collateralised Debt Security Structure"
    ],
    "classification": "complex",
    "supporting_data": "The WisdomTree US Treasuries 30Y 3x Daily Short is a fully collateralised Exchange Traded Product (ETP) that provides -3 times daily leveraged short exposure to the BNP Paribas US Treasury Ultra-Bond 30Y Rolling Future Index. The product uses a fully collateralised swap structure to achieve its investment objective, explicitly referencing swap counterparties, collateral held at The Bank of New York Mellon, and counterparty risk. The replication method is synthetic, not physical, as it tracks futures contracts rather than direct bond holdings. The product is leveraged with a factor of -3x and features daily reset and compounding effects, which increase complexity and risk. The risk indicator is at the highest level (7/7), reflecting the high volatility and risk of loss, including the possibility of losing the entire investment. The product is not UCITS compliant, which is consistent with the use of leverage and synthetic replication. The KIID and PRIIPs KID both emphasize the need for specific investor knowledge and warn that the product is not simple and may be difficult to understand. The product structure as a collateralised debt security, use of futures contracts with rolling (implying contango and roll costs), and the presence of counterparty risk further support the classification as complex. The recommended holding period is only one day, underscoring the product's short-term, sophisticated nature. These factors combined meet MiFID II criteria for complexity due to synthetic replication, leverage, inverse exposure, and derivative use as an inherent part of the strategy rather than mere risk management.",
    "risk_level_assessment": "The product is rated at the highest risk level (7/7) in the KIID, indicating very high risk consistent with leveraged, inverse, and synthetic exposure. This aligns with the MiFID II complexity classification, as the product's risk profile is elevated due to leverage, daily compounding, counterparty risk, and derivative use. The product is intended only for informed or sophisticated investors with specific knowledge, further reflecting its complexity."
}